Company profile
UK company 03028927, incorporated on 3 March 1995.
OxfordBiomedica |
Oxford Biomedica (UK) Limited is a UK company with status Active founded in 1995 based in South East England.
Company number 03028927
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Dec 2018 to 31 Mar 2019
Oxford BioMedica (OXB) is a company with broad and global market-leading capabilities in terms of development, manufacture and testing of lentiviral vectors for clinical and commercial use. As a platform and product developer OXB pioneered in vivo delivery of lentiviral vectors. Through a partnership with Novartis, OXB is the sole manufacturer of lentivir...
1 Dec 2017 to 31 Mar 2018
Oxford BioMedica (OXB) is a company with broad and global market-leading capabilities in terms of development, manufacture and testing of lentiviral vectors for clinical and commercial use. As a platform/product developer OXB pioneered in vivo delivery of lentiviral vectors, and we have several strategic partnerships, such as one with Novartis supporting ...
1 Dec 2017 to 31 Jan 2020
Cell and gene therapies offer unprecedented promise for the cure, treatment or long term management of disease. However, the challenge facing the industry is the need for viral vectors which can be consistently manufactured to commercial scale with rigorous tolerances for purity, potency and safety. This collaboration to support advanced therapies is led ...
1 Nov 2014 to 31 Mar 2018
Parkinson's disease is caused by the degeneration of nerve cells in part of the brain; leading to the loss of dopamine, a chemical messenger which plays a vital role in coordinating body movement. In early stages of PD, oral levadopa (L-DOPA) medication is effective in managing the symptoms that include tremor, muscle stiffness and slow physical movement....
1 Nov 2013 to 31 Mar 2017
Corneal transplantation is one of the most successful transplant procedures, due mainly to the relatively immune-privileged status of the eye and the fact that the cornea is largely free of blood vessels. However there is a failure rate in the first year of 14% and much higher in high rejection risk patients (such as those with failed previous grafts) due...
